Drug firm Alembic Pharmaceuticals today said it has received four observations from the US health regulator after the inspection of Panelav facility.
“The formulations facility of the company at Panelav, Halol was inspected by the USFDA from March 21 to 25. The company had received four observations which are being addressed by our regulator and quality team,” Alembic Pharmaceuticals said in a filing to BSE.
The company, however, did not provide any details about the observations it has received from the United States Food and Drug Administration (USFDA).
According to the company’s website, formulations accounts for around 65 per cent of the total business for Alembic Pharmaceuticals. It has three manufacturing facility for formulations —— Vadodara and Panelav at Gujarat and Baddi in Himachal Pradesh.
Stock of Alembic closed at Rs 573.50 on BSE, down 2.02 per cent from the previous close.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.